Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease

Graves' disease (GD) is an autoimmune disorder caused by autoantibodies against the thyroid stimulating hormone receptor (TSHR) leading to overstimulation of the thyroid gland. Thyroid eye disease (TED) is the most common extra thyroidal manifestation of GD. Therapeutic options to treat TED are...

Celý popis

Podrobná bibliografie

Vydáno v:	Frontiers in endocrinology (Lausanne) Ročník 14; s. 1211473
Hlavní autoři:	Gulbins, Anne, Horstmann, Mareike, Daser, Anke, Flögel, Ulrich, Oeverhaus, Michael, Bechrakis, Nikolaos E., Banga, J. Paul, Keitsch, Simone, Wilker, Barbara, Krause, Gerd, Hammer, Gary D., Spencer, Andrew G., Zeidan, Ryan, Eckstein, Anja, Philipp, Svenja, Görtz, Gina-Eva
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 26.06.2023
Témata:	autoimmune disorder Endocrinology Graves’ disease (GD) IGF-1R inflammation linsitinib thyroid eye disease (TED) Graves’ disease (GD) thyroid eye disease (TED) IGF-1R inflammation autoimmune disorder linsitinib
ISSN:	1664-2392, 1664-2392
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!